Drug-induced Genetic Mutation: a Descriptive Study

Adverse medication reactions are one of the main challenges that patients face throughout phar-macological treatment. The FDA’s post-marketing safety surveillance program for pharmaceuticals and ther-apeutic biologic products is intended to be aided by the FAERS database. This was a retrospective, descriptive analysis that was conducted to analyze drug-induced genetic mutation from the FDA Adverse Event Reporting System. One thousand five hundred sixty-five reports were submitted to FAERS. The most reported medications were imatinib mesylate (15.14%), lamivudine (7.41%), cyclophosphamide (6.65%), nilotinib (5.62%), dasatinib (4.66%), eculizumab (4.54%), rituximab (4.41%), tenofovir disoproxil fumarate (3.83%), etoposide (3.51%), doxorubicin (3.45%), and prednisone (3.32%). It is necessary to continue and systematically monitor the safety of these medications to avoid unnecessary adverse events. Health care providers should report these adverse events to pharmacovigilance systems.